IN BRIEF: Verona Pharma Says Third Quarter Loss Widens

Verona Pharma PLC - clinical-stage biopharmaceutical company - Pretax loss in third quarter ended ...

Alliance News 29 October, 2020 | 7:09PM
Email Form Facebook Twitter LinkedIn RSS

Verona Pharma PLC - clinical-stage biopharmaceutical company - Pretax loss in third quarter ended September 30 widens to USD22.2 million from USD15.7 million a year earlier. For nine-months to September, loss stretches to USD47.1 million from USD38.7 million.

Current stock price: 51.00 pence

Year-to-date change: down 18%

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies       Modern Slavery Statement